New Zealand’s Pharmac Agrees To Cover Two Merck Scabies Drugs
This article was originally published in PharmAsia News
Executive Summary
New Zealand’s Pharmac drug purchasing has agreed to cover, almost immediately, Merck’s Singulair (montelukast) for asthmatics, including children under the age of five years who have recurrent wheezing.